Adaptation and Virulence of Enterovirus-A71.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
21 08 2021
Historique:
received: 21 07 2021
revised: 18 08 2021
accepted: 19 08 2021
entrez: 28 8 2021
pubmed: 29 8 2021
medline: 29 1 2022
Statut: epublish

Résumé

Outbreaks of hand, foot, and mouth disease caused by enterovirus-A71 (EV-A71) can result in many deaths, due to central nervous system complications. Outbreaks with many fatalities have occurred sporadically in the Asia-Pacific region and have become a serious public health concern. It is hypothesized that virulent mutations in the EV-A71 genome cause these occasional outbreaks. Analysis of EV-A71 neurovirulence determinants is important, but there are no virulence determinants that are widely accepted among researchers. This is because most studies have been done in artificially infected mouse models and because EV-A71 mutates very quickly to adapt to the artificial host environment. Although EV-A71 uses multiple receptors for infection, it is clear that adaptation-related mutations alter the binding specificity of the receptors and allow the virus to adopt the best entry route for each environment. Such mutations have confused interpretations of virulence in animal models. This article will discuss how environment-adapted mutations in EV-A71 occur, how they affect virulence, and how such mutations can be avoided. We also discuss future perspectives for EV-A71 virulence research.

Identifiants

pubmed: 34452525
pii: v13081661
doi: 10.3390/v13081661
pmc: PMC8402912
pii:
doi:

Substances chimiques

Viral Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Références

Front Microbiol. 2021 Jan 13;11:610568
pubmed: 33519765
Virol Sin. 2020 Feb;35(1):21-33
pubmed: 31664644
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14753-8
pubmed: 23959904
PLoS Pathog. 2013;9(7):e1003511
pubmed: 23935488
PLoS Pathog. 2019 Nov 15;15(11):e1007863
pubmed: 31730673
Emerg Microbes Infect. 2016 Jun 22;5:e60
pubmed: 27329847
J Med Virol. 2002 Jun;67(2):207-16
pubmed: 11992581
PLoS Pathog. 2005 Oct;1(2):e11
pubmed: 16220146
Virology. 2017 Jan 15;501:79-87
pubmed: 27875780
Emerg Microbes Infect. 2018 Dec 5;7(1):205
pubmed: 30518755
PLoS One. 2013;8(2):e57591
pubmed: 23451246
PLoS Pathog. 2015 Jul 16;11(7):e1005033
pubmed: 26181772
Nat Microbiol. 2019 Mar;4(3):414-419
pubmed: 30531980
J Virol. 2011 Nov;85(22):11809-20
pubmed: 21900167
PLoS One. 2011;6(10):e26237
pubmed: 22039449
J Virol. 2018 Apr 13;92(9):
pubmed: 29467312
Antiviral Res. 2017 Jan;137:67-75
pubmed: 27864074
PLoS One. 2014 Mar 26;9(3):e92719
pubmed: 24671184
Viruses. 2020 Aug 13;12(8):
pubmed: 32823486
Virus Res. 2000 Jul;68(2):127-36
pubmed: 10958984
Nature. 2006 Jan 19;439(7074):344-8
pubmed: 16327776
J Med Virol. 2006 Feb;78(2):254-62
pubmed: 16372302
J Virol. 2018 Jul 17;92(15):
pubmed: 29848582
N Engl J Med. 1999 Sep 23;341(13):929-35
pubmed: 10498487
Virology. 2012 Jan 5;422(1):132-43
pubmed: 22078110
Clin Infect Dis. 2000 Sep;31(3):678-83
pubmed: 11017815
J Virol. 2004 Aug;78(15):7916-24
pubmed: 15254164
J Virol. 2017 Nov 14;91(23):
pubmed: 28931688
PLoS Pathog. 2018 Aug 3;14(8):e1007190
pubmed: 30075025
Annu Rev Microbiol. 2005;59:587-635
pubmed: 16153180
Virus Res. 2012 Jul;167(1):86-96
pubmed: 22575826
J Virol. 2016 Sep 12;90(19):8592-604
pubmed: 27440896
J Virol. 2015 Apr;89(8):4527-38
pubmed: 25673703
J Virol. 2008 Feb;82(4):1787-97
pubmed: 18057246
J Virol. 2013 Mar;87(6):3335-47
pubmed: 23302872
Emerg Infect Dis. 2012 Dec;18(12):2002-5
pubmed: 23194699
J Med Virol. 2012 Jun;84(6):931-9
pubmed: 22499017
PLoS Biol. 2018 Jun 28;16(6):e2006459
pubmed: 29953453
J Biomed Sci. 2020 Jan 10;27(1):23
pubmed: 31924205
Lancet. 1999 Nov 13;354(9191):1682-6
pubmed: 10568570
Virus Res. 2012 May;165(2):151-6
pubmed: 22406130
Emerg Microbes Infect. 2016 Sep 21;5(9):e104
pubmed: 27651091
J Gen Virol. 2005 May;86(Pt 5):1391-1401
pubmed: 15831951
J Virol. 2014 May;88(10):5816-33
pubmed: 24623428
J Virol. 2014 May;88(10):5803-15
pubmed: 24623423
J Gen Virol. 2011 Feb;92(Pt 2):287-91
pubmed: 20943886
J Virol. 2011 May;85(10):4937-46
pubmed: 21389126
Nat Med. 2009 Jul;15(7):794-7
pubmed: 19543284
Cold Spring Harb Perspect Biol. 2011 Jul 01;3(7):
pubmed: 21690215
J Virol. 2013 Jan;87(1):611-20
pubmed: 23097443
Am J Trop Med Hyg. 2007 Jul;77(1):188-91
pubmed: 17620652
J Gen Virol. 2008 Jul;89(Pt 7):1622-1632
pubmed: 18559932
Vaccine. 2016 May 23;34(24):2729-36
pubmed: 27102822
J Virol. 2019 May 15;93(11):
pubmed: 30894476
Virology. 2010 Jan 5;396(1):1-9
pubmed: 19906393
PLoS Pathog. 2020 Mar 18;16(3):e1008428
pubmed: 32187235
J Virol. 2012 Feb;86(4):2121-31
pubmed: 22130542
Lancet. 2012 Jul 21;380(9838):206
pubmed: 22826834
Arch Virol. 2003 Jul;148(7):1369-85
pubmed: 12827466
J Virol. 2018 Jul 17;92(15):
pubmed: 29848584
PLoS One. 2013;8(3):e59501
pubmed: 23527208
Nat Med. 2009 Jul;15(7):798-801
pubmed: 19543282
PLoS Pathog. 2010 Nov 04;6(11):e1001174
pubmed: 21079683
BMC Microbiol. 2012 Aug 01;12:162
pubmed: 22853823
PLoS Pathog. 2012;8(7):e1002826
pubmed: 22910880
Sci Rep. 2020 Jan 13;10(1):159
pubmed: 31932599

Auteurs

Kyousuke Kobayashi (K)

Neurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.

Satoshi Koike (S)

Neurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH